CG Oncology (CG Oncology) Other Long Term Assets : $0.05 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Other Long Term Assets?

CG Oncology's other long-term assets for the quarter that ended in Mar. 2024 was $0.05 Mil.

CG Oncology's quarterly other long-term assets increased from Sep. 2023 ($1.63 Mil) to Dec. 2023 ($4.69 Mil) but then stayed the same from Dec. 2023 ($4.69 Mil) to Mar. 2024 ($0.05 Mil).

CG Oncology's annual other long-term assets declined from Dec. 2021 ($0.09 Mil) to Dec. 2022 ($0.03 Mil) but then increased from Dec. 2022 ($0.03 Mil) to Dec. 2023 ($4.69 Mil).

CG Oncology Other Long Term Assets Historical Data

The historical data trend for CG Oncology's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Other Long Term Assets Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Other Long Term Assets

0.09

0.03

4.69

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial			0.03	-	1.63	4.69	0.05

CG Oncology Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024